Ocugen, Inc. Form 10-K Summary
Business context and reporting period
Ocugen is a biotechnology company developing gene therapies, cell therapies, biologics, and inhaled vaccines. This audited Form 10-K covers the fiscal year ended December 31, 2023, with comparative 2022 information presented on a restated basis. The company operates as one segment and has not generated revenue from product sales.
- Pipeline: OCU400 gene therapy for retinitis pigmentosa and Leber congenital amaurosis; OCU410 and OCU410ST for geographic atrophy and Stargardt disease; OCU200 for diabetic eye diseases and wet AMD; NeoCart for knee cartilage repair; and OCU500, OCU510, and OCU520 inhaled vaccines.
- Development status: OCU400 received FDA clearance to begin a Phase 3 RP trial in April 2024. OCU410 and OCU410ST remained in Phase 1/2 development at year-end. OCU200 remained on FDA clinical hold. NeoCart was Phase 3-ready, subject to funding. OCU500 was selected for NIAID Project NextGen clinical trials.
Financial performance and liquidity
| Metric | 2023 | 2022, restated | Change |
|---|---|---|---|
| Collaborative arrangement revenue | $6.0 million | $2.5 million | +$3.5 million |
| Research and development expense | $39.6 million | $56.2 million | -$16.6 million |
| General and administrative expense | $32.0 million | $35.4 million | -$3.4 million |
| Loss from operations | $(65.5) million | $(89.1) million | +$23.5 million |
| Net loss | $(63.1) million | $(86.8) million | +$23.7 million |
| Net loss per share | $(0.26) | $(0.40) | Improved |
| Cash used in operating activities | $(62.1) million | $(60.1) million | $(2.0) million |
- Cash and cash equivalents were $39.5 million at December 31, 2023, versus $77.6 million at December 31, 2022. Marketable securities of $13.4 million at year-end 2022 matured during 2023.
- Total assets were $64.5 million and stockholders’ equity was $40.6 million at December 31, 2023.
- Accounts payable and accrued expenses were $16.5 million; operating lease liabilities totaled $4.1 million; and debt carrying value was $2.8 million, including $2.5 million of principal borrowings under the EB-5 Loan Agreement.
- Property and equipment increased to $17.3 million from $6.1 million, primarily reflecting construction and renovation of the GMP facility.
- Stock-based compensation was $9.2 million, compared with $10.5 million in 2022. Unrecognized stock-based compensation was $8.6 million at year-end.
- Debt financing and equity offerings provided $20.9 million of net financing cash flow in 2023. The company issued 30.0 million shares in a May 2023 offering and sold 4.5 million shares under its former at-the-market agreement.
Material changes versus the prior comparable period
- Revenue increased because of greater co-development services under the CanSinoBIO collaboration. This revenue is primarily non-product collaborative arrangement revenue and is subject to significant estimation of variable consideration and performance progress.
- Research and development expense declined mainly because of the termination of the COVAXIN program, lower OCU200 preclinical activity, and lower OCU400 co-development services. NeoCart CMC spending increased.
- General and administrative expense declined despite a $2.8 million increase in legal expenses, primarily due to lower consulting, pre-commercial, office-opening, insurance, and employee-related costs.
- In April 2023, the FDA placed the OCU200 IND on clinical hold for additional CMC information. The hold had not been lifted as of the filing.
- Following cancellation of U.S. EUAs for monovalent COVID-19 vaccines, Ocugen determined that further development of COVAXIN in North America was not commercially viable and recorded a $4.1 million impairment of its COVAXIN supply advance, along with a $0.4 million loss on related fixed-asset disposal.
- The company completed renovation of its GMP facility and increased construction in progress to $14.5 million.
Restatement and internal controls
- The company restated its 2022 annual financial statements and specified 2022 and 2023 interim periods because it had not appropriately accounted for estimated non-cash consideration and expenses in collaboration arrangements.
- The restatement increased 2022 net loss by $5.5 million to $86.8 million and increased year-end 2022 accrued liabilities by $10.1 million, with a corresponding reduction in accumulated deficit and stockholders’ equity.
- Management identified a material weakness in internal control over financial reporting related to the accounting for collaborative arrangement revenue, including transaction-price estimation, progress measurement, and valuation of non-cash consideration.
- Disclosure controls and procedures were deemed ineffective as of December 31, 2023 and the prior year. Remediation plans include adding qualified accounting resources, improving information received from counterparties, and increasing review procedures. The weakness was not considered remediated at filing.
Guidance, outlook, commentary, and risks
- Management expects 2024 research and development and general and administrative expenses to decline because of reduced headcount, lower legal expenses, and cost-saving initiatives.
- Cash and cash equivalents were expected to fund operations into the fourth quarter of 2024. Management stated that substantial additional capital is required and that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Management plans to pursue equity or debt financing, strategic collaborations, licensing transactions, asset sales, and government funding. Financing may be unavailable or dilutive, and failure to obtain funding could delay, reduce, or eliminate development programs or lead to strategic alternatives or cessation of operations.
- OCU400 Phase 3 RP dosing was planned for the second quarter of 2024, with potential LCA expansion in the second half of 2024 subject to FDA alignment. These are forward-looking plans, not completed milestones as of the fiscal year-end.
- NeoCart Phase 3 initiation was targeted for the second half of 2024, contingent on adequate funding. OCU500 clinical trials were expected to begin in mid-2024, with NIAID covering clinical trial operations and analysis under Project NextGen while Ocugen supplies trial materials.
- Key risks include clinical and regulatory failure, the OCU200 clinical hold, limited operating history, dependence on third-party manufacturers and collaborators, competition, intellectual-property challenges, reimbursement uncertainty, potential China-related geopolitical or supply-chain restrictions, cybersecurity and data-privacy risks, and dilution from future capital raises.
- A new securities class action lawsuit was filed in April 2024 concerning previously issued financial statements and disclosure controls. The company considers the claims meritless, but the outcome and potential loss could not be estimated.
- The company regained compliance with Nasdaq’s minimum bid-price requirement in March 2024, but continued compliance with all listing requirements remains a risk.
Most important facts for investors to verify
- Whether the restated financial statements, collaboration revenue estimates, and related contract liabilities are reliable and whether the material control weakness has been remediated.
- The company’s post-year-end cash balance, monthly cash burn, financing activity, and ability to fund operations beyond the fourth quarter of 2024.
- Regulatory status, enrollment, safety data, and endpoint design for the OCU400 Phase 3 trial.
- Whether the FDA has lifted the OCU200 clinical hold and whether the company can obtain required CMC and regulatory clearances.
- Funding availability and timing for the NeoCart Phase 3 program and the inhaled vaccine programs.
- The financial and operational effects of the COVAXIN termination, CanSinoBIO collaboration, NIAID support, and other licensing arrangements.
- Outstanding debt maturities, lease commitments, license milestones, royalties, and potential dilution from equity, options, RSUs, warrants, or convertible preferred stock.
- The status and potential exposure associated with the April 2024 securities litigation and the stayed derivative actions.